uniQure price target lowered to $38 from $56 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on uniQure (QURE) to $38 from $56 and keeps a Neutral rating on the shares. uniQure shares fell about 50% after the FDA withdrew support for a BLA submission of AMT-130 in Huntington’s disease, citing insufficient evidence from the Phase 1/2 trial to establish efficacy, the analyst tells investors in a research note. The agency highlighted limitations in the study’s design and reliance on post-hoc comparisons to external controls. The regulatory path forward remains uncertain as uniQure seeks further FDA engagement under breakthrough therapy designation and awaits meeting minutes for clarification, Goldman says.